Brennan Kevin M.
SEC CIK 1971303 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | SVP, Fin AND ACCOUNTING | 6,371 | — | $2,936 | 4 | 2025-01-01 | 2026-01-02 |
Most active insiders at XLO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Shannon James Samuel | Dir | $43.9K | — |
| 2 | Frankenfield Christopher James | CFO | — | $4,499 |
| 3 | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | — | $1,169 |
| 4 | Luptakova Katarina | Chief MEDICAL Off | — | — |
| 5 | Russo Rene | Pres AND CEO, Dir | — | — |
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-01-05 | 2026-01-01 | XLO | Xilio Therapeutics, Inc. | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | M - OptEx | — | +5,000 | 8,197 | +156% | — |
| DT | 2026-01-05 | 2026-01-02 | XLO | Xilio Therapeutics, Inc. | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | S - Sale+OE | $0.64 | -1,826 | 6,371 | -22% | -$1,169 |
| D | 2025-01-03 | 2025-01-02 | XLO | Xilio Therapeutics, Inc. | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | S - Sale+OE | $0.98 | -1,803 | 3,197 | -36% | -$1,767 |
| D | 2025-01-03 | 2025-01-01 | XLO | Xilio Therapeutics, Inc. | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | M - OptEx | — | +5,000 | 5,000 | New | — |
Purchase Sale Sale after option exercise All abbreviations